Perioperative continuation of bDMARDs and tsDMARDs increases infection risk but reduces disease flare, and management should be individualized, considering drug-specific risks, including biomarker suppression and thromboembolism.
Highlights • Tofacitinib improved ASAS response in ankylosing spondylitis patients.• It ameliorated disease activity, physical function, and quality of life.• 5 mg dose and 16-week treatment showed most favorable efficacy trends.• Safety similar to placebo except for higher risk of upper respiratory infection.
Le Shen, K. Han, Lei Bo et al.· Clinics· 0 citations
There is limited data on factors predicting the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) in Spondyloarthritis (SpA) and Psoriatic arthritis (PsA). The relative importance of objective inflammation and other patient factors in this context is unclear. A retr...
Mohaned Hameed, S. Exarchou, Ankita Sharma et al.· BMC Rheumatology· 0 citations
Background: Biologic therapies have transformed Thyroid Eye Disease (TED) management, but their comparative efficacy, safety, durability and effects on subsequent rehabilitative surgery remain uncertain.
Objective: To evaluate the efficacy and safety of teprotumumab, rituximab and tocilizumab across TED phenotypes and...
N. Yadav, S. Kundan, Swati Singh et al.· Journal of Ophthalmology and...· 0 citations
Rheumatoid arthritis (RA) requires lifelong treatment with disease‐modifying antirheumatic drugs (DMARDs). In patients with sustained disease control, DMARD de‐escalation has been proposed to lessen treatment burden, but its efficacy and safety remain elusive. We conducted a systematic review and meta‐analysis of rando...
Xiao-Yan Zhang, R. K. Pandey, Xi Luo et al.· Clinical and Translational S...· 0 citations
Background Prebiotics, probiotics, and synbiotics have been proposed as adjunctive treatments for acute pancreatitis (AP), but their clinical efficacy and safety remain uncertain. We conducted a systematic review and meta-analysis to evaluate their effects on recovery-related, efficacy, and safety-critical outcomes in...
Ji Sun, Jun Zheng, Ye Shen· Frontiers in Medicine· 0 citations
Discontinuation of denosumab (DMAb) causes a rapid rebound in bone turnover and increases the risk of multiple vertebral fractures. However, the optimal sequential antiresorptive strategy and its specific timing remain uncertain.
We systematically searched PubMed, Embase, Web of Science, and Cochrane Libra...
Qi-Wen Bao, Xuan Tang, Han Miao et al.· BMC Musculoskeletal Disorder...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.